Cerebrospinal fluid metabolomics reveals predictive biomarkers of nusinersen therapy efficacy in type II and type III spinal muscular atrophy patients
Neurological Sciences · 2025
DOI: 10.1007/s10072-025-08267-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, 2025. Verfasst von Dan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, the Second Affiliated Hospital of Xi'an Jiaotong University, No.157 Xiwu road, Xi'an, 710004, Shaanxi province, China. Hauptthemen laut MEDLINE: Oligonucleotides, Metabolomics, Spinal Muscular Atrophies of Childhood. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Project of Shaanxi Province.
Abstract (Originalsprache)
Background and purpose This study investigated the predictive value of clinical characteristics and cerebrospinal fluid (CSF) metabolites for nusinersen efficacy in children with spinal muscular atrophy (SMA).
Methods
In this study, clinical data and CSF samples were collected. We used liquid chromatography-tandem mass spectrometry to analyze CSF metabolites from 42 patients with type II and type III SMA.
Results
Although clinical indicators, such as age at treatment initiation and disease duration, did not predict the clinical efficacy of nusinersen, we identified 47 differentially expressed metabolites between effective- and ineffective-treatment patients with type II disease and 109 metabolites in patients with type III disease. Additionally, KEGG-enriched pathway analysis revealed differences in several pathways between the effective- and ineffective-treatment groups for both types II and III. N-myristoyl arginine and 1,1,1,2,2,2-Pentafluoro-7-phenylheptan-3-one were negatively associated with Hammersmith Functional Motor Scale Expanded changes in patients with type III and type III SMA. Furthermore, multivariate receiver operating characteristic curve analysis indicated that differential metabolites have some accuracy in predicting SMA treatment efficacy.
Conclusion
This study identified CSF metabolites that are predictive of nusinersen efficacy. The results of this study may guide the development of adjunctive therapies for improving the efficacy of nusinersen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, the Second Affiliated Hospital of Xi'an Jiaotong University, No.157 Xiwu road, Xi'an, 710004, Shaanxi province, China.
- Department of Pediatrics, Hanzhong Central Hospital, Hanzhong, Shaanxi, China. 3458622@qq.com.
- Department of Pediatrics, the Second Affiliated Hospital of Xi'an Jiaotong University, No.157 Xiwu road, Xi'an, 710004, Shaanxi province, China. 13772152983@163.com.
Förderung
- Key R&D Project of Shaanxi Province
Zitieren
APA
Li, D., Sun, N., Wu, H., Wang, X., Shi, Y., Yang, L., Huang, S., Zhang, K., & Yang, C. (2025). Cerebrospinal fluid metabolomics reveals predictive biomarkers of nusinersen therapy efficacy in type II and type III spinal muscular atrophy patients. Neurological Sciences. https://doi.org/10.1007/s10072-025-08267-8
Vancouver
Li D, Sun N, Wu H, Wang X, Shi Y, Yang L, et al. Cerebrospinal fluid metabolomics reveals predictive biomarkers of nusinersen therapy efficacy in type II and type III spinal muscular atrophy patients. Neurological Sciences. 2025. doi:10.1007/s10072-025-08267-8
BibTeX
@article{Li2025,
author = {Li, Dan and Sun, Na and Wu, Hongbo and Wang, Xueying and Shi, Yongjing and Yang, Lin and Huang, Shaoping and Zhang, Kun and Yang, Changhong},
title = {Cerebrospinal fluid metabolomics reveals predictive biomarkers of nusinersen therapy efficacy in type II and type III spinal muscular atrophy patients},
journal = {Neurological Sciences},
year = {2025},
doi = {10.1007/s10072-025-08267-8}
}
EUVIMED